Latest Diagnostics News

AnteoTech has marked significant progress in battery and life sciences sectors, highlighted by a major capital raise and strategic US partnership. The company is poised to convert promising trials into sales amid expanding market opportunities.

BlinkLab Limited has delivered strong diagnostic results in its U.S. autism pilot study, exceeding FDA performance thresholds and setting the stage for a pivotal 510(k) trial. The company also expanded its clinical trial network and nears completion of its European ADHD study.

TrivarX Limited has expanded its diagnostic portfolio by acquiring the Stabl-Im brain cancer imaging technology and reported strong clinical trial results validating its single-lead ECG algorithm for depression screening in US veterans.

Micro-X Ltd has secured a historic $3.3 million order for its Rover mobile X-ray units in Malaysia, alongside a $6.2 million capital raise to fuel its expanding medical imaging and security technology pipeline.

Nexsen Limited has reported significant progress in its rapid diagnostic technologies, including a key FDA pre-submission for its GBS rapid sensor and a solid cash reserve post-IPO to support commercialisation efforts.

Lumos Diagnostics reported a strong surge in FebriDx® sales alongside positive FDA feedback, securing full Medicare reimbursement and advancing key clinical studies.

Imagion Biosystems has completed manufacturing its MagSense® HER2 imaging agent and is preparing for a key FDA submission, while appointing a new president to lead its US operations.

Control Bionics has secured a two-year US distribution agreement with AAC leader PRC-Saltillo to broaden access to its NeuroNode technology, enhancing communication options for users with complex needs.

Microba Life Sciences reports robust year-on-year growth in microbiome testing volumes and revenue, advancing towards regional break-even in Australia and the UK while progressing its therapeutic pipeline.

Archer Materials has made significant strides in its quantum computing and medical diagnostics programs, including improved carbon qubit readout and clinical-standard silicon biochips, while securing key partnerships and maintaining a strong cash position.

INOVIQ Limited has completed a $10.2 million capital raise to accelerate development of its exosome-based ovarian cancer screening test and CAR-exosome therapeutics, alongside key leadership appointments and promising preclinical results.

Cleo Diagnostics has broadened its U.S. market opportunity to around 2 million women annually and is on track to complete its pivotal clinical trial early this year, supported by a $5 million capital raise and regulatory progress.